Greenstone LLC recalled 3,456 cartons of methylprednisolone tablets on January 15, 2026. The recall follows reports of incorrect dosing information due to misapplied blister foil. Consumers should stop using the product immediately and contact their healthcare provider.
Labeling: Not Elsewhere Classified. Incorrect orientation of the blister foil applied to the blister cavities, which results in incorrect dosing information when following the directions on the foil.
Consumers and healthcare providers should stop using this product immediately. Contact Greenstone Llc or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
This recall affects methylprednisolone tablets, USP Dosepak, 4 mg, distributed by Greenstone LLC. The product comes in a carton containing 21 tablets and has an NDC of 59762-4440-2. The affected lot number is LG7675, with an expiration date of November 2026.
The recall stems from incorrect orientation of the blister foil on the tablets. This misorientation leads to incorrect dosing information, posing a risk of improper medication administration.
No specific incidents of injury or adverse effects have been reported as a result of this recall. However, the potential for incorrect dosing represents a significant risk.
Stop using the affected methylprednisolone tablets immediately. Contact Greenstone LLC or your healthcare provider for further guidance and information on obtaining a refund.
For more information, consumers can visit the FDA recall page or call Greenstone LLC directly. Additionally, healthcare providers should advise patients accordingly.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.